Skip to main content
Log in

ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into “Precision Oncosurgery” in Colorectal Liver Metastases

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18; discussion 318–321.

    Article  CAS  Google Scholar 

  2. Brudvik KW, Jones RP, Giuliante F, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg. 2019;269(1):120–6.

    Article  Google Scholar 

  3. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–43.

    Article  CAS  Google Scholar 

  4. Kobayashi S, Takahashi S, Takahashi N, et al. Survival outcomes of resected BRAF V600E mutant colorectal liver metastases -A multicenter retrospective cohort study in Japan. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08817-8.

  5. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15.

    Article  CAS  Google Scholar 

Download references

Funding

This study received financial support from the National Cancer Center Research Development Fund (Research no. 30-A-8; principal investigator: Shinichiro Takahashi).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shin Kobayashi MD, PhD.

Ethics declarations

Disclosure

Hiroya Taniguchi received honoraria from Takeda, Chugai, and Taiho pharmaceutical companies. Takayuki Yoshino received research funding from Novartis Pharma K.K., MSD.K.K., Sumitomo Dainippon Pharma Co., Ltd., CHUGAI PHARMACEUTICAL CO., LTD., Sanofi K.K., DAIICHI SANKYO COMPANY, LIMITED, PAREXEL International Inc., ONO PHARMACEUTICAL CO., LTD., and GlaxoSmithKline K.K.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, S., Takahashi, S., Yoshino, T. et al. ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into “Precision Oncosurgery” in Colorectal Liver Metastases. Ann Surg Oncol 27, 3316–3317 (2020). https://doi.org/10.1245/s10434-020-08818-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08818-7

Navigation